US Executive Compensation Proxy SEC Filings — July 31, 2026

31-07-2026

RF Acquisition Corp II (RFAIR) is seeking shareholder approval to extend its business combination deadline from August 15, 2026 to February 15, 2027, through up to six additional one-month extensions, each requiring a $75,000 deposit into the trust account. The company has already signed a definitive Business Combination Agreement with Nanyang Biologics Pte. Ltd. on October 2, 2025, but the deal is awaiting SEC review and Nasdaq listing approval. If the extension proposals are not approved and no business combination is completed by the current deadline, the company will liquidate and redeem public shares at the trust account value.

• · The company has already taken nine one-month extensions from November 15, 2025 to August 15, 2026, each requiring a $0.03 per share deposit (max $60,000).
• · The proposed new extensions require a higher deposit of $75,000 per month.
• · The Trust Agreement Amendment also eliminates the company's right to withdraw up to $100,000 of interest from the Trust Account for dissolution expenses.
• · The Business Combination Meeting is expected on or about August 19, 2026, approximately one week after the Extraordinary General Meeting.
• · If the extension is not approved and no business combination closes by August 15, 2026, the company will liquidate and public shares will be redeemed at the trust account value; rights will expire worthless.
• · The initial shareholders (Sponsor, EBC, directors and officers) waived their rights to participate in any liquidating distribution on their 2,875,000 Founder Shares.

31-07-2026

AstroNova, Inc. is seeking shareholder approval for a merger with an affiliate of Arcline Investment Management LP, where shareholders will receive $29.00 per share in cash. The Board unanimously recommends the merger, and Rockefeller Financial LLC has opined that the consideration is fair from a financial point of view. However, the merger involves potential conflicts of interest for directors and executive officers, including accelerated vesting of equity awards and change-in-control benefits.

• · The Special Meeting will be held virtually on August 25, 2026, at 9:00 a.m. Eastern Time.
• · Record date for voting is July 29, 2026.
• · Shareholders must register by August 24, 2026, at 11:59 p.m. Eastern Time to attend the virtual meeting.
• · The merger requires approval of a majority of outstanding shares of common stock.
• · Outstanding stock options with exercise prices below $29.00 will be cashed out; options with exercise prices at or above $29.00 will be cancelled for no consideration.
• · RSUs, PSUs, and RSAs will fully vest and be cashed out at $29.00 per share.
• · Stock-settled performance awards will be cancelled and converted into cash payments determined by the Human Capital and Compensation Committee.
• · The Merger Agreement includes a 'no solicitation' provision prohibiting the Company from soliciting alternative takeover proposals.
• · Alexis P. Michas, a director, is affiliated with Juniper, which holds approximately 6.8% of outstanding shares.

31-07-2026

Methode Electronics, Inc. filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders to be held virtually on September 16, 2026. Stockholders will vote on four proposals: election of seven director nominees, approval of the 2026 Omnibus Incentive Plan, ratification of Ernst & Young LLP as independent auditor for fiscal 2027, and an advisory vote on executive compensation. The Board recommends a 'FOR' vote on all proposals. As of the record date (July 23, 2026), there were 35,494,942 shares of common stock outstanding.

• · Annual Meeting will be held virtually on September 16, 2026 at 11:00 a.m. EDT.
• · Record date for voting is July 23, 2026.
• · Proposals include election of seven directors, approval of 2026 Omnibus Incentive Plan, ratification of EY as auditor, and advisory say-on-pay vote.
• · Board recommends FOR all proposals.
• · All directors except CEO Jonathan DeGaynor are independent under NYSE and SEC standards.
• · Broker non-votes will have no effect on Proposals 1, 2, and 4; abstentions count as votes against all proposals.

31-07-2026

CPI Aerostructures Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Shareholders to be held on September 16, 2026. Shareholders will vote on the election of two Class I director nominees (Richard Caswell and Terry Stinson), an advisory 'Say on Pay' resolution on executive compensation, and the ratification of CBIZ CPAs P.C. as the independent auditor for fiscal year 2026. The Board recommends a 'FOR' vote on all proposals. As of the record date of July 22, 2026, the company had 13,249,734 shares of common stock outstanding.

• · Annual Meeting will be held on September 16, 2026 at 1:00 p.m. at 91 Heartland Boulevard, Edgewood, New York.
• · Notice of internet availability of proxy materials to be mailed on or about July 31, 2026.
• · Record date for voting is July 22, 2026.
• · Board is divided into three classes with staggered three-year terms.
• · Class II directors (Pamela Levesque, Richard C. Rosenjack, Jr.) terms expire at 2027 annual meeting; Class III directors (Carey Bond, Michael Faber, Dorith Hakim) terms expire at 2028 annual meeting.
• · Election of directors is by plurality of votes cast; abstentions and broker non-votes have no effect.
• · Say on Pay and auditor ratification require majority of votes cast; abstentions and broker non-votes have no effect on these proposals.
• · Ratification of CBIZ CPAs P.C. is a routine matter, so brokers may vote uninstructed shares.

31-07-2026

Crinetics Pharmaceuticals is being acquired by Vertex Pharmaceuticals in an all-cash merger valued at $85.00 per share. The transaction, approved unanimously by Crinetics' board, requires shareholder approval at a special meeting on August 28, 2026. The filing also includes a non-binding advisory vote on executive compensation related to the merger and an adjournment proposal.

• · Special meeting to be held virtually on August 28, 2026 at 9:00 a.m. Pacific Time.
• · Record date for voting is July 27, 2026.
• · Merger requires approval by holders of at least a majority of outstanding shares.
• · Shareholders have appraisal rights under Delaware law.
• · Proxy statement first mailed on or about July 31, 2026.

31-07-2026

Aptevo Therapeutics Inc. filed a definitive proxy statement (DEF 14A) for its 2026 annual meeting of stockholders to be held virtually on August 21, 2026. The meeting will include the election of two director nominees, ratification of Baker Tilly US, LLP as auditor for 2026, a non-binding advisory vote on 2025 executive compensation (Say-on-Pay), and approval of the Fourth Amended and Restated 2018 Stock Incentive Plan. As of the record date of July 23, 2026, there were 1,517,945 shares of common stock outstanding and entitled to vote.

• · Annual meeting will be held virtually on August 21, 2026 at 10 a.m. Pacific Time at www.virtualshareholdermeeting.com/APVO2026.
• · Proxy materials first mailed on or about July 31, 2026.
• · Proposals include: election of two directors, ratification of auditor, advisory vote on 2025 executive compensation, and approval of stock incentive plan.
• · Board recommends voting FOR all proposals.

31-07-2026

Vistagen Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on July 31, 2026, for the 2026 Annual Meeting of Stockholders to be held virtually on September 10, 2026. The meeting will include the election of four director nominees, a non-binding advisory vote on named executive officer compensation, and ratification of KPMG LLP as the independent auditor for fiscal year ending March 31, 2027. As of the record date of July 22, 2026, the company had 44,376,911 shares of common stock outstanding.

• · Annual Meeting will be held virtually on September 10, 2026 at 9:00 am Pacific Daylight Time.
• · Record date for voting is July 22, 2026.
• · Proxy materials are being distributed via the Notice and Access method starting July 31, 2026.
• · The company's fiscal year ended March 31, 2026; Annual Report on Form 10-K was filed with the SEC on June 15, 2026.

31-07-2026

Interparfums Inc. filed a definitive proxy statement (DEF 14A) on July 31, 2026 for its annual meeting scheduled on September 15, 2026. The meeting will include election of nine directors, an advisory vote on executive compensation, and approval of a ten-year extension of the 2016 Stock Option Plan. Key shareholders Jean Madar (22.1%) and Philippe Benacin (21.4%) together control 43.5% of outstanding shares, ensuring strong insider alignment.

• · Record date for voting is July 22, 2026
• · All directors and officers as a group beneficially own 43.6% of common stock (13,987,418 shares)
• · Jean Madar holds 7,066,841 shares indirectly through holding company plus 10,500 directly
• · Philippe Benacin holds 6,846,064 shares indirectly through holding company
• · Broker non-votes and abstentions count as present for quorum but only votes cast count for director election
• · Shareholders will vote on advisory executive compensation resolution and stock option plan extension

31-07-2026

Netlist, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held on September 18, 2026. The meeting will include the election of three directors and ratification of Macias Gini & O'Connell LLP as independent auditor for fiscal year ending January 2, 2027. The filing provides standard governance and compensation disclosures but contains no financial results or material operational updates.

• · Record date for voting is July 22, 2026.
• · Proxy materials will be made available beginning August 5, 2026.
• · The meeting will be held at UCI Research Park, Cypress Room, 5301 California, Irvine, California 92617.
• · Stockholders can access proxy materials online at www.astproxyportal.com/ast/27807.

31-07-2026

FibroBiologics, Inc. filed a definitive proxy statement (DEF 14A) for a Special Meeting of Stockholders to be held on September 17, 2026. The sole proposal seeks stockholder approval, under Nasdaq Listing Rule 5635(d), for the issuance of up to 8,163,266 shares of common stock upon exercise of warrants issued under a Securities Purchase Agreement dated June 25, 2026, and up to 285,714 shares upon exercise of warrants issued under an Engagement Letter with H.C. Wainwright & Co., LLC. The Board recommends a FOR vote, and CEO Pete O'Heeron, who holds all 125 shares of Series C Preferred Stock (each with 13,000 votes), has irrevocably granted the Board the proxy to vote those shares FOR the proposal, representing approximately 20% of total eligible votes.

• · The Special Meeting will be held virtually on September 17, 2026 at 11:00 a.m. Central Time.
• · Record date for voting is July 20, 2026.
• · Notice of Internet Availability of proxy materials will be mailed on or about July 31, 2026.
• · Each share of Series C Preferred Stock carries 13,000 votes; all 125 shares are held by Pete O'Heeron.
• · The Board holds an irrevocable proxy to vote the Series C Preferred Stock on all matters (except amendments affecting O'Heeron's rights).
• · The Board will cast the 1,625,000 Series C Preferred votes FOR the proposal, representing ~20% of total eligible votes.
• · No other matters are expected to be brought before the Special Meeting.
• · Approval requires a majority of shares present and entitled to vote; abstentions count as votes against, and there are no broker non-votes.

31-07-2026

Muzinich BDC, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on September 18, 2026. Stockholders will vote on the election of one Class I director and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026. The Board unanimously recommends voting 'FOR' both proposals.

• · Annual Meeting will be held virtually on September 18, 2026 at 9:00 AM Eastern Time.
• · Record date for voting is July 27, 2026.
• · A quorum requires at least one-third of outstanding common stock.
• · Requests to attend virtually must be received by 11:59 PM Eastern Time on September 17, 2026.
• · Proxy materials first sent to stockholders on or about July 31, 2026.

31-07-2026

Muzinich Corporate Lending Income Fund, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on September 18, 2026. Stockholders will vote on the election of one Class I director and the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026. The Board unanimously recommends voting 'FOR' both proposals.

• · Annual Meeting will be held virtually on September 18, 2026 at 9:00 AM Eastern Time.
• · Record date for voting is July 27, 2026.
• · Quorum requires at least one-third of outstanding common stock.
• · Proxy materials first sent to stockholders on or about July 31, 2026.
• · Stockholders may attend virtually by emailing attendameeting@equiniti.com with subject line 'Muzinich Corporate Lending Income Fund, Inc. Annual Meeting' by 11:59 PM ET on September 17, 2026.